Le nirmatrelvir-ritonavir (Paxlovid®), un traitement contre la Covid-19

The nirmatrelvir-ritonavir (Paxlovid®) is a treatment against Covid-19 available in pharmacies since February 4, 2022. Administered orally, it is intended only for people at very high risk of contracting one or more severe forms of the disease.

Detalles Bibliográficos
Autores principales: Buxeraud, Jacques, Faure, Sébastien, Fougere, Édouard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2022
Materias:
Nouveautés
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304942/
https://www.ncbi.nlm.nih.gov/pubmed/35891982
http://dx.doi.org/10.1016/j.actpha.2022.05.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304942/
https://www.ncbi.nlm.nih.gov/pubmed/35891982
http://dx.doi.org/10.1016/j.actpha.2022.05.002

Ejemplares similares